Lipocine (NASDAQ: LPCN) notes progress in Phase 3 postpartum trial

Rhea-AI Filing Summary

Lipocine Inc. filed a report describing clinical progress for its investigational drug LPCN 1154 in postpartum depression. On January 12, 2026, the company issued a press release stating there was encouraging progress following the second interim safety review in its Phase 3 trial of LPCN 1154. The press release is provided as an exhibit to the report and is incorporated by reference.

Insights

Biotech and clinical-trials analyst

Encouraging Phase 3 safety review supports continued testing of LPCN 1154.

Lipocine Inc. reports encouraging progress after a second interim safety review in the Phase 3 trial of LPCN 1154 for postpartum depression. A positive safety signal at this stage typically means an independent review has not identified major safety concerns that would halt the study.

The focus on postpartum depression highlights a significant unmet medical need, so advancing a Phase 3 asset here can be strategically important. However, the disclosure highlights safety progress only and does not provide efficacy data or detailed metrics on outcomes.

Further updates, particularly on efficacy results or trial completion, will be important to understand LPCN 1154’s potential in postpartum depression. For now, the information indicates that the Phase 3 program is proceeding after the second interim safety assessment.

false 0001535955 0001535955 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

January 12, 2026

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware		99-0370688
(State or other jurisdiction of incorporation)		(IRS Employer Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 12, 2026, the Company issued a press release reporting encouraging progress post second interim safety review in Phase 3 Trial of LPCN 1154 in postpartum depression. The press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description
99.1		Press Release announcing Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			LIPOCINE INC.
Date:	January 12, 2026		By:	/s/ Mahesh V. Patel
				Mahesh V. Patel
				President and Chief Executive Officer

FAQ

What did Lipocine Inc. (LPCN) report in this 8-K filing?

Lipocine Inc. reported that it issued a press release describing encouraging progress after the second interim safety review in its Phase 3 trial of LPCN 1154 for postpartum depression.

What is LPCN 1154 in Lipocine’s (LPCN) clinical program?

LPCN 1154 is an investigational drug being evaluated by Lipocine Inc. in a Phase 3 clinical trial for the treatment of postpartum depression.

What stage is Lipocine’s LPCN 1154 postpartum depression trial?

The trial of LPCN 1154 for postpartum depression is in Phase 3, and the company reported encouraging progress following a second interim safety review.

Does the Lipocine (LPCN) filing provide detailed trial results for LPCN 1154?

The filing states that a press release reported encouraging progress after the second interim safety review in the Phase 3 trial but does not include detailed trial results in the text provided.

What exhibit is included with Lipocine’s 8-K on LPCN 1154?

The filing includes Exhibit 99.1, a press release titled "Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression."

Why is the Phase 3 interim safety review for LPCN 1154 important for Lipocine (LPCN)?

An interim safety review in a Phase 3 trial helps determine whether a study can continue as planned; reporting encouraging progress suggests no major safety issues have stopped the LPCN 1154 postpartum depression trial.